Spironolactone attenuates oxidative stress in patients with chronic kidney disease.
Renke
Marcin
M
Tylicki
Leszek
L
Knap
Narcyz
N
Rutkowski
Przemyslaw
P
Neuwelt
Alexander
A
Larczynski
Wojciech
W
Wozniak
Michal
M
Rutkowski
Boleslaw
B
D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology*; D001562:Benzimidazoles / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D002908:Chronic Disease; D017315:Cilazapril / Q000627:therapeutic use; D003404:Creatinine / Q000652:urine; D018592:Cross-Over Studies; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D007674:Kidney Diseases / Q000188:drug therapy / Q000503:physiopathology* / Q000652:urine; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D013148:Spironolactone / Q000494:pharmacology*; D000077333:Telmisartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D001562:Benzimidazoles; D001565:Benzoates; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D006852:Hydrochlorothiazide; D017315:Cilazapril; C075750:8-epi-prostaglandin F2alpha; D013148:Spironolactone; D003404:Creatinine; D015237:Dinoprost; D000077333:Telmisartan